Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

By Kenneth R. Hess, K. Anderson, W. Symmans, V. Valero, N. Ibrahim, J. Mejia, D. Booser, R. Theriault, Aman U. Buzdar, P. J. Dempsey and 8 more. Journal of Clinical Oncology, 2006

715 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/f0bcf1803d30ac3dd1570da8d4a732e657749e53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

GENOMIC PREDICTOR OF RESPONSE AND SURVIVAL FOLLOWING TAXANE-ANTHRACYCLINE CHEMOTHERAPY FOR INVASIVE BREAST CANCER (2011, neutral): “1 19 (8) 1 (1) 20 (6) 8 (9) 1 (1) 1 (2) 10 (5)”
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models (2010, methodology): “Genomic analysis of a subset of this sequentially accrued patient population were reported previousl”
A Constrained ℓ1 Minimization Approach to Sparse Precision Matrix Estimation (2011, methodology): “‖Ω̂ρ −Ω0‖2 ≤ C4s0(p)λ n , (14) and 1 p ‖Ω̂ρ −Ω0‖(2)F ≤ C5s0(p)λ n (15) where C4 ≤ 2(1 + 2 + 3)(4‖Ω0‖L1) and C5 ≤ 4‖Ω0‖L1C4.”
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes (2010, background): “Anderson Cancer Center study of response to neoadjuvant chemotherapy with paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide (54), we asked if tumor geneexpression profiles from patients that had a pathological complete response (pCR) correlated with the EMT core signature.”
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy (2011, methodology): “The neoadjuvant cohort consisted of 2 gene expression cohorts representing 311 patients treated with neoadjuvant chemotherapy (26, 27), with complete pathologic response in 60 (19%) patients.”
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells (2014, methodology): “On the basis of these associations, we next evaluated two published data sets annotated for pathologic complete response (pCR) following treatment with CTX (Hess et al., 2006; Tabchy et al., 2010).”
Deconstructing the molecular portraits of breast cancer (2010, background): “For example, in a combined data set of w400 tumors/patients (UNC337 (Prat et al., 2010) and MDACC133 (Hess et al., 2006)) (Figure 6A), 49% of triple-negative tumors were Basal-like, 30% Claudin-low, 9% HER2-enriched, 6% Luminal B, 5% Luminal A and 1% Normal Breast-like; if the Claudin-low…”
A Projection-based Conditional Dependence Measure with Applications to High-dimensional Undirected Graphical Models. (2015, methodology): “In this study, we use the normalized gene expression data of 130 patients with stages I-III breast cancers analyzed by Hess et al. (2006). Among the 130 patients, 33 of them achieved pCR (class 1), while the other 97 patients did not achieve pCR (class 2).”
GOBO: Gene Expression-Based Outcome for Breast Cancer Online (2011, neutral): “A multitude of microarray-based gene signatures have been derived stratifying breast cancer into subtypes [1,2,24], identifying patients at risk [5,6,8,9,11,12], and predicting response to therapeutic agents [3,4].”
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013, methodology): “Gene expression levels were derived by exposing the microarray to fluorescent probe sets (multiple oligonucleotide probes that hybridize to specific sequences of gene transcripts) (13, 14).”
Jetset: selecting the optimal microarray probe set to represent a gene (2011, methodology): “We next evaluated a second publicly-available breast cancer data set for which clinical HER2 status based on protein immunohistochemistry or on fluorescence in situ hybridization (FISH) was annotated in 132 breast tumors [20].”